Denovicon Therapeutics
Denovicon Therapeutics is a drug discovery company aiming to accelerate and improve the process of developing small-molecule therapeutics. They utilize a proprietary AI-driven platform combining machine learning, generative therapeutic design, and physics-based approaches to identify and optimize drug leads. Their platform screens billions of molecules to find high-quality leads, streamlining the drug discovery process and reducing R&D timelines and costs. Denovicon focuses on targets in DNA damage response (DDR) pathways and immuno-oncology, specifically progressing first-in-class molecules targeting PARP1 and PARP2 for oncology, immunology, neuroscience, and cardiovascular diseases, as well as PARP7 for oncology indications. The company highlights an 80% success rate in a project on next-generation PARP1 inhibitors and a 59% success rate in their first-in-class PARP7 project, both using a high bar of 50% inhibition at 1µM as the cutoff. Denovicon also emphasizes its strategic collaboration with Biovia and Dassault Systèmes.
Denovicon Therapeutics
Denovicon Therapeutics is a drug discovery company aiming to accelerate and improve the process of developing small-molecule therapeutics. They utilize a proprietary AI-driven platform combining machine learning, generative therapeutic design, and physics-based approaches to identify and optimize drug leads. Their platform screens billions of molecules to find high-quality leads, streamlining the drug discovery process and reducing R&D timelines and costs. Denovicon focuses on targets in DNA damage response (DDR) pathways and immuno-oncology, specifically progressing first-in-class molecules targeting PARP1 and PARP2 for oncology, immunology, neuroscience, and cardiovascular diseases, as well as PARP7 for oncology indications. The company highlights an 80% success rate in a project on next-generation PARP1 inhibitors and a 59% success rate in their first-in-class PARP7 project, both using a high bar of 50% inhibition at 1µM as the cutoff. Denovicon also emphasizes its strategic collaboration with Biovia and Dassault Systèmes.